Researchers look back at Real-World results for breast cancer drug sequence
NCT ID NCT06961331
Summary
This study looked back at medical records to understand how well a three-drug combination (tucatinib, trastuzumab, and capecitabine) works for people with advanced HER2+ breast cancer after they have already received a different treatment called T-DXd. It involved 86 patients from a large health database. The goal was to measure real-world outcomes like how long patients stayed on the treatment and overall survival.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC HER2+ ADVANCED BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer
New York, New York, 10001, United States
Conditions
Explore the condition pages connected to this study.